Head-to-head evidence
DA-1726 vs PB-718
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1/glucagon receptor (dual) · full Obesity pipeline
DA-1726
Developed by MetaVia
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: November 2026 · NCT06252220 (registry estimate)
PB-718
Developed by PegBio
NCT06147544 · Phase 1/2 · completed
The study randomized 36 participants to PB-718 or matched placebo and masked both participants and investigators, but its small sample and safety-focused primary endpoint make it a limited trial for judging clinical benefit. No primary-endpoint results have been posted, so whether the treatment-emergent adverse-event comparison was favorable cannot be determined.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: DA-1726's landscape · PB-718's landscape